Table 2.
Microorganism profile for the patients in the study cohort
| 28-day survivors n = 235 | 28-day non-survivors n = 104 | P value | |
|---|---|---|---|
| Gram-positive isolates (n, %) | 16 (6.8%) | 11 (10.6%) | 0.2772 |
| S.Aureus | 12 (5.1%) | 10 (9.6%) | 0.1505 |
| MRSA | 2 (0.9%) | 0 (0) | 1 |
| Streptococcus spp. | 1 (0.4%) | 0 (0) | 1 |
| Enterococcus spp. | 2 (0.9%) | 1 (1.0%) | 1 |
| Other | 1 (0.4%) | 0 (%) | 1 |
| Gram-negative isolates (n, %) | 158 (67.2%) | 52 (50.0%) | 0.0035 |
| Acinetobacter baumannii | 76 (32.3%) | 37 (35.6%) | 0.6175 |
| Klebsiella spp. | 59 (25.1%) | 26 (25.0%) | 1 |
| Pseudomonas spp. | 50 (21.3%) | 13 (12.5%) | 0.0687 |
| Enterobacter spp. | 24 (10.2%) | 6 (5.8%) | 0.2177 |
| S. maltophilia | 16 (6.8%) | 3 (2.9%) | 0.2018 |
| Other | 9 (3.8%) | 4 (3.8%) | 1 |
| Fungi isolates (n, %) | 55 (23.4%) | 28 (26.9%) | 0.4959 |
| Candida albicans | 28 (11.9%) | 17 (16.3%) | 0.2985 |
| Candida glabrada | 16 (6.8%) | 2 (1.9%) | 0.0702 |
| Candida tropicalis | 7 (3.0%) | 4 (3.8%) | 0.7423 |
| Other | 4 (1.7%) | 4 (3.8%) | 0.2556 |
| Virus isolates (n, %) | 2 (0.9%) | 1 (1.0%) | 1 |
| Tuberculosis isolates (n, %) | 1 (0.4%) | 0 (0) | 1 |
Data were presented as number of isolates (percentage of current group), not number of patients. S. aureus, Staphylococcus aureus; MRSA, methicillin-resistant Staphylococcus aureus; S. maltophilia, Stenotrophomonas maltophilia; spp., species